Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | RAB9A | P51151 | 4/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.42 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.42 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | TNF | P01375 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.42 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.42 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.42 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.42 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1107151 | 0.85 | MEN1 (0.60) | MEN1KMT2ARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL29668381 | 0.85 | MEN1 (0.60) | MEN1KMT2ARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL25859075 | 0.84 | MEN1 (0.55) | MEN1KMT2ARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL9642581 | 0.82 | MEN1 (0.54) | MEN1KMT2ARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL15709794 | 0.82 | MEN1 (0.54) | MEN1KMT2ARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL7041225 | 0.82 | KMT2A (0.54) | MEN1KMT2ARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL9579673 | 0.81 | ALDH1A1 (0.58) | MEN1KMT2ARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL23736407 | 0.79 | KMT2A (0.47) | MEN1KMT2ARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL21376013 | 0.79 | MEN1 (0.51) | MEN1KMT2ARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL4090341 | 0.79 | RAB9A (0.51) | MEN1KMT2ARAB9ANPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115536641-B | Lactone compound and preparation method and application thereof | 广州润尔眼科生物科技有限公司 | 2024-12-27 | — | — | CN | disclosed |
| CN-119176806-A | Aceclidine prodrug, and preparation method and application thereof | 上海英诺富成生物科技有限公司 | 2024-12-24 | — | — | CN | disclosed |
| US-20230331696-A1 | SALT FORM OF ISOQUINOLINONE TYPE COMPOUND AS ROCK INHIBITOR AND PREPARATION METHOD THEREFOR | OCUSUN OPHTHALMIC PHARMACEUTICAL (GUANGZHOU) CO., LTD. (CN) | 2023-10-19 | — | — | US | disclosed |
| US-20230331696-A1 | SALT FORM OF ISOQUINOLINONE TYPE COMPOUND AS ROCK INHIBITOR AND PREPARATION METHOD THEREFOR | OCUSUN OPHTHALMIC PHARMACEUTICAL (GUANGZHOU) CO., LTD. (CN) | 2023-10-19 | — | — | US | disclosed |
| US-20230024516-A1 | ISOQUINOLINONE DERIVATIVES SERVING AS ROCK PROTEIN KINASE INHIBITORS AND USE THEREOF | GUANGZHOU OCUSUN OPHTHALMIC BIOTECHNOLOGY CO., LTD. (CN) | 2023-01-26 | — | — | US | disclosed |
| CN-115536641-A | Lactone compound and preparation method and application thereof | 上海英诺富成生物科技有限公司 | 2022-12-30 | — | — | CN | disclosed |
| EP-3988544-A1 | ISOQUINOLINONE DERIVATIVES SERVING AS ROCK PROTEIN KINASE INHIBITORS AND USE THEREOF | Guangzhou Ocusun Ophthalmic Biotechnology Co., Ltd. (CN) | 2022-04-27 | — | — | EP | disclosed |
| WO-2020253882-A1 | ISOQUINOLINONE DERIVATIVES SERVING AS ROCK PROTEIN KINASE INHIBITORS AND USE THEREOF | 中山大学中山眼科中心 | 2020-12-24 | — | — | WO | disclosed |
| US-7553989-B2 | Malonic acid monoesters and process for producing the same | MEIJI SEIKA KAISHA, LTD. (JP) | 2009-06-30 | — | — | US | disclosed |
| US-20050272950-A1 | Malonic acid monoesters and process for producing the same | MEIJI SEIKA KAISHA LTD. (JP) | 2005-12-08 | — | — | US | disclosed |
| EP-1561748-A1 | MALONIC ACID MONOESTERS AND PROCESS FOR PRODUCING THE SAME | MEIJI SEIKA KAISHA LTD. (JP) | 2005-08-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230024516-A1 | ISOQUINOLINONE DERIVATIVES SERVING AS ROCK PROTEIN KINASE INHIBITORS AND USE THEREOF | ROCK1, ROCK2, CIT | MEN1 2042/4885KMT2A 2301/4885RAB9A 582/4885 |
| US-20230331696-A1 | SALT FORM OF ISOQUINOLINONE TYPE COMPOUND AS ROCK INHIBITOR AND PREPARATION METHOD THEREFOR | ROCK1, ROCK2, NHERF1 | MEN1 852/4885KMT2A 2241/4885RAB9A 711/4885 |
| US-20050272950-A1 | Malonic acid monoesters and process for producing the same | ME1, SI, ME3 | MEN1 765/4885KMT2A 1463/4885RAB9A 786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.